Ryan D. Cassaday

Hematology
1959 NE Pacific St
Seattle, WA 98195

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 121 publications

Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia.

Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia.

Journal: Leukemia & lymphoma
Published: August 18, 2026

Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia.

Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia.

Journal: Transplantation and cellular therapy
Published: April 21, 2026

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.

Journal: Blood advances
Published: April 09, 2026

Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL.

Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL.

Journal: Blood advances
Published: April 09, 2026

Incidence and Risk Factors for CNS Relapse in Adult ALL after Allogeneic Hematopoietic Cell Transplantation.

Incidence and Risk Factors for CNS Relapse in Adult ALL after Allogeneic Hematopoietic Cell Transplantation.

Journal: Blood advances
Published: March 31, 2026

Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study.

Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study.

Journal: Blood
Published: February 20, 2026

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.

Journal: Blood
Published: February 20, 2026

Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.

Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.

Journal: Leukemia
Published: January 16, 2026

Patients First: Navigating Asparaginase-Based Treatment in Young Adults With Acute Lymphoblastic Leukemia.

Patients First: Navigating Asparaginase-Based Treatment in Young Adults With Acute Lymphoblastic Leukemia.

Journal: American journal of hematology
Published: December 22, 2025

Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches.

Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches.

Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025

Sanctuary sites and extramedullary relapses in the chemo-free world: insights from immunotherapies in B-ALL.

Sanctuary sites and extramedullary relapses in the chemo-free world: insights from immunotherapies in B-ALL.

Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.

Journal: Blood
Published: September 19, 2025
Showing 1-12 of 121

Last Updated: 09/26/2026